Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020
Repeatability of Quantitative
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- [European journal of nuclear medicine and molecular imaging · 2026Trial
- Deep learning-based PSMA PET segmentation repeatability: A post-hoc analysis of a single-center, prospective, test-retest trial.La Radiologia medica · 2026Trial
- High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged withMolecular imaging · 2022Trial
- Leveraging [Clinical and translational science · 2026Article
- Repeatability of semi-quantitative [European journal of nuclear medicine and molecular imaging · 2026Article
- Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics.European journal of nuclear medicine and molecular imaging · 2024Article
- Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN.Oncotarget · 2024Article
- Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives.Cancers · 2023Review
- An exploratory study of unexplained concentration ofFrontiers in medicine · 2023Article
- Prostate-Specific Membrane Antigen Targeted Pet/CT Imaging in Patients with Colon, Gastric and Pancreatic Cancer.Cancers · 2022Article
- Reliability of gradient-based segmentation for measuring metabolic parameters influenced by uptake time on 18F-PSMA-1007 PET/CT for prostate cancer.Frontiers in oncology · 2022Article
- Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma.Cancers · 2021Review
- Is SUV Corrected for Lean Body Mass Superior to SUV of Body Weight inMolecular imaging and radionuclide therapy · 2021Article
- Evaluation of Quantitative Ga-68 PSMA PET/CT Repeatability of Recurrent Prostate Cancer Lesions Using Both OSEM and Bayesian Penalized Likelihood Reconstruction Algorithms.Diagnostics (Basel, Switzerland) · 2021Article
- Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer.European journal of nuclear medicine and molecular imaging · 2021Article
- Early differences in dynamic uptake of 68Ga-PSMA-11 in primary prostate cancer: A test-retest study.PloS one · 2021Article
- Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography.Frontiers in oncology · 2021Review
- Day-to-day variability of [EJNMMI research · 2020Article
- Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy-Do Different Software Solutions Deliver Comparable Results?Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quantitative evaluation of radiolabeled prostate-specific membrane antigen (PSMA) PET scans may be used to monitor treatment response in patients with prostate cancer (PCa). To interpret longitudinal differences in PSMA uptake, the intrinsic variability of tracer uptake in PCa lesions needs to be defined. The aim of this study was to investigate the repeatability of quantitative PET/CT measurements using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.